Dyne Therapeutics director Brian S. Posner acquires $40,000 in common shares

Bitget2026/10/06 20:15

Dyne Therapeutics director Brian S. Posner bought 2,500 common shares at $16 per share. Directly held stake rose to 27,000 shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415584), on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

BUZZ - Morningstar optimistic about strong performance in canning business, Australian Aurora shares rise

路透社•2026/10/16 01:26

MSCI adopts index exclusion rules that could oust Strategy

Cointelegraph•2026/10/16 01:00

Four hours ago, a whale opened the largest leverage long positions on bitcoin and ethereum, holding positions worth 187 millions dollars.

BlockBeats•2026/10/16 00:31

No scientific evidence but viral on social media: “Bodybuilding miracle drug” peptide products deregulation file sent to the White House for review, Hims&Hers (HIMS.US) surged 6% in one day.

The temporary admission policy for peptides has been submitted to the White House for review, and compounding pharmacies are expected to receive approval to produce BPC-157 and other substances; HIMS closed up 6% on Thursday.

智通财经•2026/10/16 00:11